HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Acotec Scientific Holdings (6669.HK) - The Fall in Share Price Is Not over Yet

China Healthcare Weekly (Jan.12) - Mainstream R&D Trend, Innovent, BeiGene, Sirnaomics, ImmuneOnco

Shandong Weigao Group Medical Polymer Co (1066.HK) - 2023 Full-Year Results Could Be Ugly

WuXi XDC Cayman (2268.HK) - Would It Be An "Oasis in the Desert"?

Pre-IPO QuantumPharm - Good Stories May Not Be Backed up by Performance

2024 China’s Capital Market Outlook - Santa Claus Is Knocking on the Door

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Escalation of Israel-Hamas War - Here's How Investors Should Position Themselves in Dramatic Changes

Equity Capital Markets

<ul>
<li>The business model of MIXUE is S2B2C. The expansive and highly efficient supply chain is the bedrock of MIXUE’s industry leading performance and scale, setting it apart from its peers.</li>
<li>MIXUE has more flexibility to diversify its business to explore new growth points and is also more resilient to risks/industry changes, which determines sustainability and growth ceiling of future development.</li>
<li>As competition for freshly-made tea drinks industry intensifies, capital has become “impatient”. As an industry leader, now is the best time for an IPO. MIXUE’s valuation could reach US$10 billion.</li>
</ul>


The business model of MIXUE is S2B2C. The expansive and highly efficient supply chain is the bedrock of MIXUE’s industry leading performance and scale, setting it apart from its peers.
MIXUE has more flexibility to diversify its business to explore new growth points and is also more resilient to risks/industry changes, which determines sustainability and growth ceiling of future development.
As competition for freshly-made tea drinks industry intensifies, capital has become “impatient”. As an industry leader, now is the best time for an IPO. MIXUE’s valuation could reach US$10 billion.


Pre-IPO MIXUE Group - The Snow King Opens up a Lot More Room for Imagination than Expected

Mixue Group

Pre-IPO MIXUE Group - The Snow King Opens up a Lot More Room for Imagination than Expected